The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?

被引:12
|
作者
Tracy, Kathlene [1 ,2 ,3 ]
Wachtel, Leah [1 ]
Friedman, Teri [4 ,5 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Psychosocial Proc Addict, 1399 Pk Ave, New York, NY 10029 USA
[2] Addict Inst Mt Sinai AIMS, Psychosocial Div, 1470 Madison Ave, New York, NY 10029 USA
[3] Friedman Brain Inst FBI, 1470 Madison Ave, New York, NY 10029 USA
[4] Mt Sinai Beth Israel, Opioid Treatment Program, 103 E 125th St,3rd Floor, New York, NY 10025 USA
[5] New York State Coalit Medicat Assisted Treatment, 121 West 36th St,201, New York, NY 10018 USA
关键词
COVID-19; Opioid use disorder; Addiction services; Medication for opioid use disorders; Methadone;
D O I
10.1016/j.jsat.2021.108394
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Medication for opioid use disorder (MOUD) services is key to addressing the opioid crisis and COVID-19 has significantly impacted MOUD delivery. The need for social distancing and self-quarantining requires individuals to maintain personal physical space and limits face-to-face interactions, which are required for methadone dispensing and other regulated treatment activities. Mount Sinai Beth Israel, which has one of the largest opioid treatment service (OTP) delivery systems within the United States and included 10 OTP methadone clinics that responded rapidly by implementing procedures to address the additional challenges during the COVID-19 pandemic. This article discusses four key procedural areas: 1) verified identity in-person pick-up doses, 2) drug urine toxicology screens, 3) treatment interactions, and 4) discharges, which can inform future OTP operational procedures by encouraging out-of-the-box thinking in this new age.
引用
收藏
页数:3
相关论文
共 50 条
  • [41] Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar, Tushar
    Raut, Dezaree
    Bhatt, Lokesh Kumar
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2021, 43 (01) : 8 - 21
  • [42] Laboratory biomarkers and prognosis in Covid-19, where do we stand?
    Israni, Alisha
    Goulden, Christopher J.
    Harky, Amer
    REVIEWS IN MEDICAL VIROLOGY, 2021, 31 (06)
  • [43] COVID-19 pandemic and cardiovascular disease: where do we stand?
    Chatzis, Dimitrios G.
    Magounaki, Kalliopi T.
    Pantazopoulos, Ioannis N.
    Johnson, Elizabeth O.
    Tsioufis, Konstantinos P.
    MINERVA CARDIOANGIOLOGICA, 2020, 68 (04): : 347 - 358
  • [44] COVID-19 after 18 months: Where do we stand?
    Chassagnon, Guillaume
    Regarda, Lucile
    Soyera, Philippe
    Revel, Marie-Pierre
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2021, 102 (09) : 491 - 492
  • [45] Directly Acting Antivirals for COVID-19: Where Do We Stand?
    Teoh, Siew L.
    Lim, Yi H.
    Lai, Nai M.
    Lee, Shaun W. H.
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [46] The new services that opioid treatment programs have adopted in response to COVID-19
    Cantor, Jonathan
    Laurito, Agustina
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 130
  • [47] Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to
    Probir Kumar Ojha
    Supratik Kar
    Jillella Gopala Krishna
    Kunal Roy
    Jerzy Leszczynski
    Molecular Diversity, 2021, 25 : 625 - 659
  • [48] Strengthening regulatory systems for medicines in a changed world: where do we go from here?
    O'Brien, Julie
    Lumsden, Rebecca
    Macdonald, Judith
    BMJ GLOBAL HEALTH, 2021, 6 (01):
  • [49] The impact of the COVID-19 pandemic on medications for opioid use disorder services in the US and Canada: a scoping review
    Parker, Daniel G.
    Zentner, Daysi
    Burack, Jacob A.
    Wendt, Dennis C.
    DRUGS-EDUCATION PREVENTION AND POLICY, 2023, 30 (06) : 529 - 542
  • [50] Rebound and steep increase of international travel after the COVID-19 pandemic: where are we going from here?
    Anagnostopoulos, Alexia
    Fehr, Jan
    JOURNAL OF TRAVEL MEDICINE, 2023, 31 (01)